Safety and efficacy of nab-paclitaxel combined with nedaplatin and bevacizumab in patients with platinum-resistant epithelial ovarian cancer: a retrospective cohort study | Synapse
March 30, 2026Open Access
Safety and efficacy of nab-paclitaxel combined with nedaplatin and bevacizumab in patients with platinum-resistant epithelial ovarian cancer: a retrospective cohort study
Key Points
The study aims to evaluate the safety and effectiveness of a chemotherapy regimen in platinum-resistant epithelial ovarian cancer.
Conducted a retrospective cohort analysis of patients receiving the chemotherapy regimen.
Included patients with a history of treatment for ovarian cancer.
Assessed the therapeutic efficacy and toxicity of nab-paclitaxel, nedaplatin, and bevacizumab.
The chemotherapy regimen showed satisfactory therapeutic efficacy.
Managed toxicity levels, indicating a viable treatment alternative for patients.
Abstract
This chemotherapy regimen demonstrated satisfactory therapeutic efficacy and manageable toxicity in heavily pretreated PROC, suggesting its potential as a viable treatment alternative.